Biotech

The cuts and restructures at CSL show the risks of relying on a few large players to carry Australia’s research and innovation forward.

CSL’s $20 billion wipeout after a shock restructure announcement dragged the ASX lower, as investors punished the biotech with its steepest fall in six years.

Melbourne-based VC Boson Ventures has raised $10 million of a target $30 million fund and is positioning itself as a bridge between Australia and China.

Australia's National Reconstruction Fund has invested $150 million in venture capital firm Brandon Capital in a bid to stop promising biotech companies from moving offshore.

Sanofi’s $1.76 billion acquisition of Vicebio delivers a windfall for the University of Queensland — and highlighted a promising model for commercialising Aussie research.